Kornimate/medical-research-clean huggingface dataset:
identification of patient phenotypes associated with elevated aldosterone levels

Conditions: Acute Heart Failure

Summary: post-discharge mortality and re-hospitalization for acute heart failure (ahf) affects 15% and 30% of patients respectively, within 90 days. with over 1 million annual hospitalizations and a financial cost exceeding 20 billion dollars, ahf is a major public health burden. yet no ahf therapy to date definitively reduces morbidity and mortality, and in stark contrast to heart attack patients, highly rated evidence in guidelines do not exist. although ahf is a syndrome and not one disease, typical treatment of patients hospitalized with ahf suggests otherwise. despite substantial differences among ahf patients, therapy is largely uniform; patients receive medicine to help get rid of excess volume and little else. although decades of empirical use support the symptomatic benefits of traditional therapies, outcomes remain extremely poor. as opposed to the "one-size-fits-all" approach used unsuccessfully to date in clinical trials, identification of specific ahf patient sub-groups is critical, so that tailored therapies can be developed and tested. preliminary data suggests that the neurohormone aldosterone may be detrimental in ahf patients. furthermore, this hormone level appears to rise during hospitalization. the investigators therefore propose to identify specific ahf patient phenotypes associated with high serum aldosterone levels to subsequently address the hypothesis that early aldosterone blockade continued throughout hospitalization will decrease re-hospitalization and mortality. specifically, the investigators hypothesize that ahf patients with elevated serum aldosterone levels have a distinct phenotype compared to those with lower or normal aldosterone levels. specifically, they will be older, have a lower systolic blood pressure, lower ef, worse renal function, higher bnp, and previous hospitalization for hf.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age * ahf is the primary working diagnosis for er management and treatment have received or will receive iv diuretic therapy * enrolled within 12 hours of initial diuretic dose order exclusion criteria: * serum cr ≥ 2.5mg/dl (males) or 2.0mg/dl (females), or egfr \< 20 ml/min/1.73m2 * serum potassium ≥ 5.5 meq/l * transplant recipients of any kind * fever \> 101.0 * severe lung disease (required home o2 or daily oral steroids) * acute coronary syndrome within last 30 days * major surgery within last 30 days * known hypertrophic obstructive cardiomyopathy, pericardial constriction, or hemodynamically significant valvular disease * life expectancy less than 12 months for any reason * current treatment for any malignancy of any kind * cardiogenic shock and/or requiring iv inotropic therapy * pregnant or recently pregnant within last 90 days * known intolerance to aldosterone antagonist * inability to give appropriate written consent

Keywords: aldosterone echocardiography neurohormones
efficacy of a new nanoemulsion artificial tear targeting dry eye disease

Conditions: Dry Eye Syndromes

Summary: this is a prospective cohort study to compare subjective changes in symptoms using the ocular surface disease index (osdi) questionnaire, following the recommended dosage of the new nanoemulsion eye drops (systane complete)in mild to moderate dry eye patients, and to investigate objective ocular surface changes using modern clinical instruments during the study period.

this study, lasting for 3 months in total, is to investigate the changes in both subjective reports (osdi score) and objective measurements (non-invasive tear break time (nitbut) and other clinical signs such as corneal staining) after the use of this nanoemulsion eye drops (systane complete). subjects are required to use the eyedrop qid for 3 months, and come back for follow-up at 2-week and 3-month visits. other secondary measurements such as meibography and lipid layer thickness, will also be investigated.

Eligibility criteria:
inclusion criteria: 1. age 20-50 years old 2. best corrected distance visual acuity ≥ 6/9 3. mild to moderate osdi score 13-32 4. any one of the objective test positive (nitbut/corneal fluorescein staining/tear osmolarity) exclusion criteria: 1. any active ocular infections 2. inflammations or anomalies in the eyelid 3. uncontrolled, newly diagnosed systemic diseases or with modified long-term medications within 6 months that are known to affect tear profile. 4. pregnancy and breastfeeding 5. contact lens wearers are required to stop contact lenses wear for at least 1 week before the evaluation. 6. subjects who are using artificial tears or other eyedrops will be excluded. 7. subjects who are taking systemic drugs that may cause dry eye, e.g., antidepressants/antipsychotics, systemic corticosteroids.
progressive eccentric vs bodyweight exercises on agility, power and functional performance in hamstring strain.

Conditions: Exercise Movement Techniques; Exercise Therapy; Hamstring Injury

Summary: the study is randomized and single blinded. ethical approval is taken from ethical committee of riphah international university lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a and group b through sealed envelope method by non probability convenient random sampling technique. subjects in group a will receive progressive eccentric exercises. group b will receive bodyweight exercises.

the objective of the study is to determine the effects of progressive eccentric exercises verses bodyweight exercises on agility, power and functional performance in athletes with hamstring strain. the study is randomized and single blinded. ethical approval is taken from ethical committee of riphah international university lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a and group b through sealed envelope method by non probability convenient random sampling technique. subjects in group a will receive progressive eccentric exercises. group b will receive bodyweight exercises. the outcome measures will be assessed by t test, vertical jump, standing long jump and squat test. the data will be analyzed by spss, version 25. statistical significance is p=0.05.

Eligibility criteria:
inclusion criteria: * athletes older than of 18 years will be added. athletes having history of hamstring strain of grade 1 and 2.participants will be added after 4 weeks of recovery period after grade 1 \& 2 hamstring strain.male and female athletes will be added. exclusion criteria: * athletes with a complete rupture of the hamstring muscle. athletes undergone hamstring surgery in the past 6 months will not be considered.participants with history of back pain.lower limb injuries in past 6 months. if the hamstring strain is accompanied by severe associated injuries, such as fracture or significant ligament tear.

Keywords: progressive eccentric exercises bodyweight exercises hamstring strain
physical activity and breast cancer risk in postmenopausal women:the shape study

Conditions: Breast Cancer

Summary: purpose of the shape study is to examine the effects of an 1-year exercise programme on endogenous hormone levels associated with breast cancer among sedentary postmenopausal women and whether a decrease in intra-abdominal fat is associated with a lowering of these hormone levels.

physical activity has been associated with a decreased risk for breast cancer. the biological mechanism(s) underlying the association between physical activity and breast cancer is not clear. most prominent hypothesis is that physical activity may protect against breast cancer through reduced lifetime exposure to endogenous hormones. another hypothesis is that physical activity prevents overweight and abdominal adiposity. in this intervention study, 189 sedentary postmenopausal women who are aged 50-69 years are randomly allocated to an intervention or a control group. the intervention consists of an 1-year moderate-to-vigorous intensity aerobic and strength training exercise programme. participants allocated to the control group are requested to retain their habitual exercise pattern. primary study parameters measured at baseline, at four months and at 12 months are: serum concentrations of endogenous estrogens, endogenous androgens, sex hormone binding globulin and insulin. other study parameters include: amount of total and abdominal fat, weight, bmi, body fat distribution, physical fitness, blood pressure and lifestyle factors. this study will contribute to the body of evidence relating physical activity and breast cancer risk and will provide insight into possible mechanisms through which physical activity might be associated with reduced risk of breast cancer in postmenopausal women.

Eligibility criteria:
inclusion criteria: * women aged 50 -69 year * \> 12 months since last menses * non-smokers (at least 12 months) * sedentary * knowledge of the dutch language * agreement to be randomly assigned to either the exercise intervention or control group * informed consent to participate in all screening and study activities exclusion criteria: * use of hormone replacement or oral contraceptives in past 6 months * morbidly obese (bmi \> 40) * bmi \< 22 * currently on or planning to go on a strict diet * ever diagnosed with breast cancer * diagnosis of other types of cancer in the past 5 years * diabetes mellitus or other endocrine related diseases * disorders or diseases (locomotor, optical, neurological, mental) that might impede the participation in the exercise programme * alcohol or drug abuse * maintenance use of corticosteroids * use of beta blockers

Keywords: physical activity sex steroid hormones breast cancer risk intervention study postmenopausal women
monitoring of covid-19 vaccine response in organ transplant patients

Conditions: Covid19; Kidney Transplantation

Summary: vaccination against sars cov-2 appears to be the best strategy today to control the covid-19 pandemic. the first published studies with pfizer, moderna and astra-zeneca vaccines show very good vaccine protection in the general population and good short-term tolerance. the efficacy of these vaccines ranges from 62 to 95%, which is particularly remarkable, especially for mrna vaccines. nevertheless, these studies do not report the vaccine response in organ transplant patients. it is known that transplant patients have lower vaccine responses than immunocompetent patients due to some degree of immunosuppression. therefore, the investigators are interested in evaluating the vaccine response of organ transplant recipients after vaccination against sars- cov-2. for non-responder patients, new strategies can be proposed: 3rd or 4th boost of vaccine or perfusion/injection of antis monoclonal antibodies. these strategies must be evaluated.


Eligibility criteria:
inclusion criteria: * patient, male or female, adult or child (15 years and older) * patient vaccinated against sars-cov-2 as part of routine care, and having received the 2 injections * solid organ transplant recipient * transplantation for more than 3 months exclusion criteria: * history of anaphylactic shock or known allergy to peg * known history of covid or positive covid serology in the 3 months preceding inclusion * formal contraindication to an intra-muscular injection * impossibility to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...) * subject under legal protection * subject under guardianship or curatorship * patient having expressed his opposition to participate

Keywords: covid19 kidney transplantation seroconversion immunosuppression vaccination
evaluation by ultrasound imaging of local anesthetic spread to the popliteal fossa during an adductor canal block

Conditions: Knee Injuries

Summary: adductor canal block is an effective analgesic technique for major knee surgery. however, the saphenous nerve block is not sufficient to explain this block's efficiency. it has been shown that adductor canal block can spread to the tibial and fibular nerves through the adductor hiatus. however this diffusion's frequency has never been measured. the main objective of this study is to assess the frequency of the spread of the adductor canal block to the fibular and tibial nerves assessed by ultrasound observation at the popliteal fossa.

adductor canal block is an effective analgesic technique for major knee surgery. the prospect group recommends this block in first intention for locoregional anesthesia in total knee arthroplasty. it has been shown to not be inferior to femoral nerve block in this indication. the adductor canal block targets the saphenous nerve and, through its spread in the adductor canal, the posterior branch of obturator nerve and the vastus medialis nerve. however these nerves can't fully explain this block's efficiency. it has been shown that local anesthetic can spread in the adductor canal to the tibial and fibular nerves through the adductor hiatus. however, this spread is inconstant, and no study has evaluated the frequency of this spread yet. the main objective of this study is to assess the diffusion's frequency of adductor canal block to fibular and tibial nerves through ultrasound observation at the popliteal fossa.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective knee surgery under general anesthesia * in center of ambroise paré hospital * receiving an adductor canal block exclusion criteria: * patients cognitively impaired * patients suffering from peripheral neuropathy at the lower limb * patients receiving an ipack block or surgical knee infiltration to complete the adductor canal block analgesia * patients who refused to take part in this study * pregnant or breastfeeding patients * patients under guardianship * imprisoned patients * patients without any medical insurance

Keywords: knee surgery ultrasound analgesia pain
behavior therapy for irritability in autism

Conditions: Autism Spectrum Disorder; Irritability; Disruptive Behavior; Anger; Aggression; Asperger Syndrome; Pervasive Developmental Disorder

Summary: this is a clinical trial of a novel intervention, behavioral therapy for irritability and aggression (btia), for adolescents on the autism spectrum. the main goals of btia are to help adolescents develop emotion regulation skills to handle frustration and to strengthen skills for navigating the challenging and diverse experiences associated with the transition to adulthood. the study will test whether btia can be helpful to adolescents on the autism spectrum and to their families.

this is a randomized controlled study of btia versus a supportive therapy control condition in 126 adolescents (ages 12 to 18 years) with a diagnosis of autism spectrum disorder and significant levels of disruptive behaviors such as aggression, anger outbursts, and oppositional behavior. btia consists of 15 ninety-minute weekly sessions that will be conducted with the teens and their parents by therapists using a structured, detailed manual. the effects of btia on the reduction of behavioral problems will be rated by an experienced clinician who does not know which treatment each participant is receiving (a "blinded" evaluator). study participants will receive a thorough diagnostic assessment of autism spectrum disorder and other forms of psychopathology that may co-occur with asd. in addition to testing the effects of btia on disruptive behavior, the changes in adaptive functioning, or children's ability to function competently in their everyday environment, will be examined before and after treatment.

Eligibility criteria:
inclusion criteria: * boys and girls, ages 12 to 18 years inclusive * diagnosis of autism spectrum disorder * presence of disruptive behaviors such as irritability and anger outbursts * no planned changes in the intensity of current treatment(s) * medication free or on stable medication * sufficient language for participation in verbal therapy * lives within driving distance from new haven, ct exclusion criteria: * presence of a medical condition that would interfere with participation in the study * presence of a current psychiatric disorder that requires immediate clinical attention

Keywords: autism adolescents behavior therapy treatment disruptive behavior irritability anger aggression
participant reported outcomes with use of trifarotene 50 μg/g cream in the treatment of moderate facial and truncal acne vulgaris

Conditions: Acne Vulgaris

Summary: participant reported outcomes with use of trifarotene 50 μg/g cream in participants with moderate facial and truncal acne vulgaris

there was no formal hypothesis to be tested. approximately 50 subjects would be enrolled to evaluate the subject reported outcomes (quality of life and satisfaction survey). the sample size was not based on any formal hypothesis testing.

Eligibility criteria:
inclusion criteria: * the participant was a male or female, 9 years of age or older, at screening visit. * the participant had moderate acne at screening and baseline. * the participant was a female of non childbearing potential. * the participant was a female of childbearing potential with a negative pregnancy test and who was strictly abstinent or who agreed to use an effective and approved contraceptive method for the duration of the study and at least 1 months after the last study drug application. exclusion criteria: * the participant had severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g., chloracne, drug induced acne, etc.). * the participant had any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the participant at significant risk (according to the investigator's judgment) if the participant took part to the trial. * the participant had been exposed to excessive ultraviolet (uv) radiation within one month prior to the baseline visit or the participant was planning intense uv exposure during the study (i.ed, occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.). * the participant was unwilling to refrain from use of prohibited medication during the clinical trial.
high-dose steroid for hip arthroplasty patients expected to have postoperative pain

Conditions: Postoperative Pain; Postoperative Nausea and Vomiting; Hip Osteoarthritis; Perioperative/Postoperative Complications; Surgery; Opioid Use; Catastrophizing Pain; Chronic Pain

Summary: the purpose of the study is to test a higher dose of steroids(dexamethasone) given just prior to surgery in the setting of fast-track hip-surgery with arthroplasty in a group of expected high pain responders and the effect on postoperative pain and postoperative inflammation.

this study compares a new high-dose dosage of steroids in the treatment of postoperative pain after hip arthroplasty in a fast-track setting in a group of expected high pain responders. the investigators compare the already used dose(medium dose) with a new high dose(hd) steroid given as an intravenous bolus after the spinal anaesthesia has been given, but before the surgery starts. the hypothesis is that by attenuating the inflammatory response to the surgery itself by the steroid dexamethasone, the investigators expect a reduction in postoperative pain upon ambulation 24 hours after unilateral hip arthroplasty. patients referred to unilateral total hip arthroplasty because of hip-osteoarthritis at hvidovre hospital, capital region of denmark or vejle hospital, south region of denmark are screened and offered inclusion in the study. the two groups will be randomized and double blinded. one group will be treated, as the current guideline in the investigator's orthopedic fast-track arthroplasty center, with the medium dose of steroid (0,3 mg dexamethasone/kg bodyweight). the other group wil be treated with a high dose of steroid (1,0 mg dexamethasone/kg bodyweight). the patients will be monitored the first 7 days after surgery, during the admission to the hospital, and by a pain-diary in the patients own home. blood tests will be taken preoperatively and postoperatively to determine the effect of the highdose steroid on the inflammatory response.

Eligibility criteria:
inclusion criteria: * age between 40 and 90. * booked for unilateral hip-arthroplasty. * is able to take part in the investigation(selfreported pain and nausea/vomiting) * understands danish or english, or has a translator available. * signed written consent. * a daily use of 30 mg or more of morphine or morphine equivalents . * a pain catastrophizing scale(pcs) score of \>20. exclusion criteria: * insulin-dependent diabetes melitus. * ongoing treatment with systemic glucocorticoids or immunosuppressing treatment(apart from inhaled glucocorticoids). * pregnancy/breastfeeding * allergies for the investigational drug. * a history of schizophrenia or bipolar diseases, or patients with permanent use of antipsychotic medication.

Keywords: hip arthroplasty hip replacement perioperative medicine
pilot study to assess cat-2003 in patients with hyperlipidemia

Conditions: Dyslipidemia; Hypercholesterolemia; Hypertriglyceridemia

Summary: the purpose of this study is to determine the safety and efficacy of different doses of cat-2003 in patients with hyperlipidemia when cat-2003 is taken for 4 weeks. the study will evaluate effects of cat-2003 on (1) fasting triglycerides and non-hdl-c in patients with moderate hypertriglyceridemia and (2) fasting ldl-c levels in combination with a statin in patients with hypercholesterolemia who are on a statin.


Eligibility criteria:
inclusion criteria: * between 18 and 69 years at screening * hypertriglyceridemia (tg ≥ 200 mg/dl and \< 500 mg/dl and non-hdl-c ≥ 100 mg/dl and \< 220 mg/dl) or * hypercholesterolemia (ldl-c ≥ 100 mg/dl and \< 190 mg/dl and tg value \< 200 mg/dl) plus a stable dose of statin for at least 4 weeks prior to screening. * body mass index (bmi) ≤ 45 kg/m2 exclusion criteria: * history of any major cardiovascular event within 6 months of screening * type i diabetes mellitus * any condition that may predispose the patient to secondary hyperlipidemia, such as uncontrolled hypothyroidism * any statin at the highest approved dose * non-statin lipid-altering drugs other than cholesterol absorption inhibitors. * active peptic ulcer disease or a history of muscle disease or myopathy